Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI1310

Pages :148

Formats :

Excel and PDF

Industry : Pharmaceutical

Multiple Sclerosis Therapeutics Market Size and Trends

Global multiple sclerosis therapeutics market is estimated to be valued at USD 31.39 Billion in 2025 and is expected to reach USD 41.89 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4% from 2025 to 2032. Multiple sclerosis is a chronic neurological condition that affects the central nervous system. Increasing prevalence of multiple sclerosis globally can drive the market growth.

Multiple Sclerosis Therapeutics Market Key Factors

To learn more about this report, Request sample copy

Rising prevalence of multiple sclerosis

Rising prevalence of multiple sclerosis across the globe can drive the market growth. Highest rates of the disease are concentrated in Northern European countries and their former colonies such as Canada, U.S., and Australia. However, even developing nations are witnessing increase in multiple sclerosis patients. The exact cause of rising prevalence is not fully understood but experts believe that improved diagnosis and changes in environmental factors contributes to this prevalence.

Changes in lifestyle patterns across the world can influence the risk of developing multiple sclerosis. Factors like reduced exposure to sunlight, smoking, lack of physical activity and improved hygiene levels can cause autoimmune dysregulation in the human body. While genetics play an important role, environmental triggers are now considered equally important for multiple sclerosis onset and progression.

In light of continuously increasing prevalence, patient pool requiring lifelong treatment is expanding rapidly. Several health surveys project that the number of multiple sclerosis patient will increase significantly in near future, if preventive measures are not adopted on a large scale. This provides a strong rationale for biopharmaceutical firms to focus on developing innovative drugs targeting the underlying pathophysiology of multiple sclerosis with more efficiency. Sustained R&D investments are being made to bring safer and more effective treatment options to the market, in order to address the growing needs of multiple sclerosis patients worldwide.